Protein That Calms Waking Hair Follicles Could Lead to Alopecia Treatment
Led by a team from the Duke‑NUS Medical School in Singapore and the Walter and Eliza Hall Institute of Medical Research in Australia, researchers found that when MCL-1 production was blocked in mice, the animals lost their hair later in life.
Hair follicles go through cycles of quiescence and growth, with MCL-1 playing a critical role in the latter phase. The protein doesn't seem to affect the resting phase or the initial development of hair follicles, however.
"Acute MCL‑1 deletion rapidly depletes activated hair follicle stem cells and completely blocks depilation‑induced hair regeneration in adult mice, while quiescent hair follicle stem cells remain unaffected," write the researchers in their published paper.
It was already known that MCL-1 played an important role in protecting a number of different kinds of tissue from apoptosis; the programmed death of redundant or damaged cells to keep the body functioning.
When it comes to hair, MCL-1 prevents follicle stem cells from being stressed and damaged as they 'reawaken' from rest. Without MCL-1 to protect them, these cells stop functioning.
The team was also able to reveal new details on MCL-1's function, identifying ways it suppresses another protein called BAK and how MCL-1 is regulated by a signaling pathway called ERBB. These details could be useful in developing new methods of hair loss treatments.
"These findings suggest that ERBB signaling modulates MCL‑1 expression through translational control mechanisms, particularly during periods of heightened apoptosis and regression in the hair cycle," the researchers write.
The study was based solely on mice, so while there's good reason to think the same processes are happening on the top of our own heads, the findings will need to be replicated in clinical research on humans.
It's also worth bearing in mind that there are several different kinds of alopecia, all with a variety of contributing causes: if treatments are one day developed that focus on boosting MCL-1, they're not going to work for all types of hair loss.
Those limitations aside, this one protein's handiwork is a significant revelation concerning hair follicles' ability to grow hair. The findings could also inform future studies into other processes affected by MCL-1, including cancer cell death.
"This study advances our understanding of the molecular mechanisms underlying hair follicle regeneration and offers new insights into how stem cell survival and tissue regeneration are orchestrated," write the researchers.
"These findings may have broader implications for controlling the survival of stem and progenitor cells in tissue regeneration and cancer expansion."
The research has been published in Nature Communications.
Woman's Brain Implant Turns Her Thoughts Into Speech in Real Time
Sometimes Alzheimer's Strikes Early. This Experimental Drug May Help.
Dangerous Fungal Infection Sees a Dramatic Increase in US Hospitals
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
6 hours ago
- Indianapolis Star
Texas AG sues Eli Lilly for allegedly bribing medical providers to prescribe Lilly drugs
Texas Attorney General Ken Paxton is suing Eli Lilly, alleging the Indianapolis pharmaceutical company offered kickbacks to medical providers in exchange for prescribing more than a dozen of the company's drugs, including blockbuster GLP-1 weight loss drugs Mounjaro and Zepbound. Eli Lilly offered illegal incentives to Texas medical providers, including a "free nurse" program and reimbursement support services, to steer providers to provide the company's drugs, Paxton alleges in a lawsuit filed August 11 in a Texas district court. Lilly, one of the world's largest pharmaceutical companies, denied the allegations in an August 12 statement to IndyStar. The Lilly programs mentioned in the suit offered free trainings for nurses and medical providers, which helped Lilly market their drugs when they launched, the suit says. According to Paxton's office, many Texas residents prescribed these drugs were on state Medicaid, so these actions violated the Texas Health Care Program Fraud Prevention Act. 'Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme,' Paxton said in a news release. 'Eli Lilly fraudulently sought to maximize profits at taxpayer expense and put corporate greed over people's health. I will not stand by while corporations unlawfully manipulate our healthcare system to line their own pockets.' A spokesperson for Eli Lilly said the company denies the allegations and plans to defend against them in court. It's not the first time Paxton has taken a stab at Lilly in the courts. In October, Paxton sued insulin manufacturers and pharmacy benefit managers, including Lilly, Express Scripts and CVS, for allegedly concocting a conspiracy to increase insulin prices. Health Choice Alliance LLC, a New Jersey based company, joined Texas as a plaintiff. Health Choice has sued Lilly in the past, alleging the company engages in kickbacks. 'Multiple courts and the federal government have rejected claims by this same corporate relator against Lilly as meritless," a Lilly spokesperson said in a statement. "In fact, the United States government determined that 'the relators' allegations lack sufficient factual and legal support' in a prior case, explaining that 'federal healthcare programs have a strong interest in ensuring that, after a physician has appropriately prescribed a medication, patients have access to basic product support relating to their medication.' We intend to vigorously defend against these allegations.' At the heart of the Texas lawsuit is a class of drugs named GLP-1s prescribed for diabetes and weight loss. Named for the gut hormone receptor the drug targets, injectable GLP-1s have exploded in popularity since Zepbound hit the market in late 2023. Weight loss drugs: Eli Lilly closer to breakthrough weight loss drug; shares tumble as some question results The kickback lawsuit against Lilly is one way Paxton is protecting Texas patients "from corporate schemes that undermine the integrity of the healthcare system," according to his office.
Yahoo
9 hours ago
- Yahoo
Scientists May Have Identified a Natural Alternative to Ozempic
Scientists may have identified a way to naturally regulate blood sugar levels and sugar cravings in a similar fashion to drugs like Ozempic. In mice and humans, the key to unlocking this natural process was found to be a gut microbe and its metabolites – the compounds it produces during digestion. By increasing the abundance of this one gut microbe in diabetic mice, researchers led by a team at Jiangnan University in China showed they can "orchestrate the secretion of glucagon-like peptide-1". Related: Glucagon-like peptide-1 (GLP-1) is a hormone that is naturally produced by the body and which helps regulate blood sugar levels and feelings of fullness. GLP-1's release is stimulated by certain foods and gut microbes, and its mechanism of action is mimicked by drugs like semaglutide (the ingredient behind Ozempic). People with type 2 diabetes typically have impaired GLP-1 function, leading to issues with blood sugar control, which is why Ozempic and other GLP-1 agonists work as treatments. These drugs mimic natural processes in the body, and while they have proved very effective, some researchers want to figure out how to get the body to produce more GLP-1 on its own. "A growing body of research has revealed that our cravings for dietary components originate from signals sent from the gut, a key organ in transmitting dietary preferences," explain the authors in their paper published in January. "However, which genes, gut flora, and metabolites in the gut microenvironment are involved in the regulation of sugar preference is currently unclear." The new research suggests gut microbes like Bacteroides vulgatus and their metabolites may help shape a person's sweet tooth. In experiments, if mice could not produce a gut protein, called Ffar4, the researchers found the gut colonies of B. vulgatus shrank. This, in turn, decreased the release of a hormone called FGF21, which is tied to sugar cravings. In studies of mice taking GLP-1 agonists, researchers have found the drugs stimulate FGF21. Meanwhile, in humans, some studies suggest that those with genetic variants for the FGF21 hormone are about 20 percent more likely to be top-ranking consumers of sweet foods. In a blood analysis of 60 participants with type 2 diabetes and 24 healthy controls, the researchers in China found that Ffar4 mutations, which reduce FGF21 production, are linked to an increased preference for sugar, "which may be an important contributor to the development of diabetes." What's more, the gut microbiome could be a key mediator of that process. Sure enough, the research team found that when mice were treated with a metabolite of B. vulgatus, it boosted GLP-1 secretion, which then also triggered the secretion of FGF21. Together, this meant more blood sugar control and fewer sugar cravings in mice. Whether the same will extend to humans remains to be seen, but the authors claim their study "provides a strategy for diabetes prevention." The study was published in Nature Microbiology. An earlier version of this article was first published in January 2025. Related News New Research Confirms Weight-Loss Drug Link With Sudden Vision Loss This Amazing Blob Is Stunningly Similar to The Human Brain Air Conditioning Could Put You at Risk of 'Sick Building Syndrome' Solve the daily Crossword
Forbes
14 hours ago
- Forbes
A New Chapter For Diabetes—and Regenerative Medicine
For decades, the ambitious goal of regenerative medicine has been to replace damaged or lost tissues with healthy, functioning ones. Nowhere is this objective more compelling—or challenging—than in type 1 diabetes. Countless research efforts over the years have sought to restore these cells. Breakthroughs in cell engineering and transplantation are beginning to overcome long-standing roadblocks, and these recent advances are a significant achievement for regenerative medicine as a whole. For millions living with the constant demands and worries of type 1 diabetes, this is more than promising data. It's a moment that hints at a world where glucose monitors and needles might finally become relics of the past. With this, a life free from the daily burdens of diabetes suddenly feels not just possible, but Is Type 1 Diabetes? Type 1 diabetes is a chronic autoimmune disorder defined by the immune system's destruction of insulin-producing beta cells in the pancreas. Insulin is the hormone responsible for moving glucose from the bloodstream into the body's cells for energy. Without it, blood sugar rises to dangerous levels. Over time, it can damage virtually every organ. Most people diagnosed are children or young adults, and living with type 1 diabetes requires ongoing vigilance: regular blood glucose testing, carefully calibrated insulin administration, and persistent risk of life-threatening hypoglycemia. To survive, people with type 1 diabetes must monitor their blood sugar levels constantly. They frequently perform fingerstick tests throughout the day to check their blood glucose levels. Also, they must adjust their diet, exercise routine, and daily schedule to accommodate frequent insulin injections or an insulin pump. Despite advances in technology, keeping blood glucose within a safe range remains challenging, and the risk of life-threatening 'hypoglycemic' episodes—when blood sugar drops too low—is Stem Cell Therapy: Replacing What's Lost This is where the new therapies come into play. They go straight to the heart of the problem: the loss of the body's own insulin-producing cells. Instead of requiring patients to rely on lifelong injections, the focus is now on developing stem cells grown in controlled laboratory environments. These stem cells are engineered to become fully functional islet cells. These are the very clusters that regulate blood sugar in a healthy pancreas. The "off-the-shelf" nature of these cells is crucial. Earlier islet transplant procedures relied on donated organs, which are rare, variable in quality, and subject to lengthy waitlists. The engineered cells, on the other hand, are produced in large quantities. Also, they can be made available as needed. When infused, typically into the liver, these new cells integrate and begin responding to blood sugar levels in real time, releasing insulin as needed. In essence, the therapy is designed to restore the natural balance lost due to the disease. The promise of this approach is already becoming a the Latest Study The most recent results in the development of stem cell–derived therapies for type 1 diabetes stem from a clinical trial conducted by Vertex Pharmaceuticals. This study enrolled patients with established, severe type 1 diabetes. This is a group for whom current treatments often fail to prevent sudden and dangerous drops in blood sugar. Each patient in the trial received a single infusion of lab-grown islet cells, now referred to as zimislecel. To translate the science: the stem cells are first turned into insulin-producing islet cells in the lab. These are then infused into the patient's liver, not the pancreas. If successful, they begin sensing blood sugar levels and releasing insulin as needed, just like a healthy pancreas would. Think of this as swapping out a faulty part with a working one, rather than relying on external fixes. The results over twelve months were consistent and dramatic. All participants in the study were found to be producing their own insulin again. This was confirmed by checking bloodwork to verify that the islet cells were now active. Therefore, the transplanted cells integrated well, and the patients' bodies were able to produce insulin naturally for the first time in years. Even more remarkably, ten of these individuals were able to discontinue daily insulin injections entirely. Every participant met or surpassed the American Diabetes Association's stringent targets for glycemic control. Notably, none suffered severe hypoglycemic This Matters: The Science and Its Impact These results represent a shift in the care landscape for type 1 diabetes. Previous attempts at islet cell replacement used donor cells, which were in very limited supply. By creating islets from universal stem cells, this therapy can be scaled up. It brings the possibility of universal therapies with consistent quality and availability. This offers real hope to millions worldwide. It also signals a foundational advance in regenerative medicine itself. Demonstrating that we can produce, transplant, and integrate functional cell populations to cure a chronic, complex condition illustrates the practical power of stem cell technology. The methodology used here is already being adapted for other therapeutic targets: engineered heart muscle for cardiac repair, retinal cells for vision restoration, and dopaminergic neurons for Parkinson's disease. It establishes a blueprint for tackling similar disorders and builds a bridge from bench research to real-world clinical impact. These advances, however, are not without their complexities. Because the transplanted islet cells are not the patient's own, recipients currently require immunosuppressive medications to prevent rejection—a challenge shared by all current forms of tissue and organ transplantation. Although initial safety profiles are encouraging and side effects manageable, ongoing studies are exploring methods to reduce or eliminate immune suppression, such as gene editing and immune cloaking Road Ahead: What's Next? The achievements described here are far more than incremental progress in diabetes care. They represent proof-of-concept for the broad ambitions of regenerative medicine: restoring lost tissue function, curing chronic diseases, and making transformative treatments widely accessible. As these strategies mature and diversify, their impact will almost certainly extend well beyond any single disease. They offer a pathway to fundamentally change how we approach a broad spectrum of degenerative and autoimmune conditions. The future of regenerative medicine, once hypothetical and distant, now approaches with real hope for curing—not simply managing—a host of devastating chronic conditions.
